Thomas A. Neville, PhD, Discusses PSA Growth Rate

Video

Thomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.

Thomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.

If PSA is growing early on at a considerable rate but the absolute growth is not great, a patient needs to be monitored carefully. If a patient is screened annually at this stage, depending on PSA baseline, a physician may choose to screen every three or six months. Neville says if PSA is growing at a high rate but is not yet at a high level, prostate cancer can be caught early.

The approach at Soar Biodynamics is close monitoring, annual testing, and early baseline to diagnose and treat at low PSAs. To avoid overtreatment, a physician should consider being patient with slower-growing PSAs.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine